Cargando…
Lysine Acetylation, Cancer Hallmarks and Emerging Onco-Therapeutic Opportunities
SIMPLE SUMMARY: Several histone deacetylase inhibitors have been approved by FDA for cancer treatment. Intensive efforts have been devoted to enhancing its anti-cancer efficacy by combining it with various other agents. Yet, no guideline is available to assist in the choice of candidate drugs for co...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773583/ https://www.ncbi.nlm.nih.gov/pubmed/35053509 http://dx.doi.org/10.3390/cancers14020346 |